Optinose US
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Optinose US sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).
Optinose US: 11 sponsored US clinical trials, 2 recruiting.
Optinose US sponsors 11 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 9 completed. 10 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Bilateral Nasal Polyposis, with 2 trials.
Top-decile sponsor footprint
Optinose US ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
11 total, page 1 of 1
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
NCT06850805
OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
NCT03747458
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps
NCT03960580
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps
NCT03781804
Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video
NCT03591068
Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety
NCT01622569
Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device
NCT01624662
Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps
NCT01623323
12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device
NCT01623310
Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects
NCT01507610
Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine
NCT01462812
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 10 |
Therapeutic Areas
Where Optinose US enrollment is open (later-stage tilt)
2 recruiting of 11 indexed (18% open); 9 completed (82%).
Phase mix: 10 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Bilateral Nasal Polyposis (2 trials), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Optinose US: open-pipeline peers nationwide
Peers matched on 11 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
Optinose US sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 11 trials (± recruiting share)
- Aderans Research Institute · 11 trials · 0% recruiting
- Aegerion Pharmaceuticals · 11 trials · 0% recruiting
- Allena Pharmaceuticals · 11 trials · 0% recruiting
- AOBiome · 11 trials · 0% recruiting
Sponsors near 18% open enrollment (± trial volume)
- Burke Medical Research Institute · 18% recruiting · 11 trials
- Grand Valley State University · 18% recruiting · 11 trials
- Imunon · 18% recruiting · 11 trials
- InventisBio Co. · 18% recruiting · 11 trials
Related
What to do with this Optinose US page
11 registered trials is a research-attention snapshot, not an endorsement of Optinose US or any single study.
- 2 of Optinose US's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Bilateral Nasal Polyposis is the condition Optinose US studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Bilateral Nasal Polyposis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Optinose US pipeline card: 11 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.